HIV vaccine vCP2438

Drug Profile

HIV vaccine vCP2438

Alternative Names: ALVAC-HIV-vCP2438; vCP2438

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi Pasteur
  • Developer GlaxoSmithKline; Sanofi Pasteur
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III HIV-1 infections

Most Recent Events

  • 19 Jun 2017 Phase-I/II clinical trials in HIV-1 infections (Prevention) in Mozambique and Zimbabwe (IM) (NCT03284710)
  • 19 Jun 2017 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase I/IIa trial for HIV-1 infections (Prevention) in South Africa (IM) (NCT03284710)
  • 17 Apr 2017 National Institute of Allergy and Infectious Diseases plans a phase I/II trial of HIV vaccine vCP2438 and MF59®- or AS01B-adjuvanted bivalent subtype C gp120 for HIV infections in South Africa, Tanzania, Zambia and Zimbabwe (NCT03122223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top